v3.26.1
Segment and Geographic Data (Tables)
3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
Segment Results
Three Months
2026
2025
MedSurg and Neurotechnology
$3,207
$3,056
Orthopaedics
2,813
2,810
Net sales
$6,020
$5,866
MedSurg and Neurotechnology
$1,291
$1,175
Orthopaedics
823
775
Cost of sales
$2,114
$1,950
MedSurg and Neurotechnology
$231
$208
Orthopaedics
146
158
Segment research, development and
engineering expenses
$377
$366
MedSurg and Neurotechnology
$930
$859
Orthopaedics
880
925
Segment selling, general and
administrative expenses
$1,810
$1,784
MedSurg and Neurotechnology
$55
$48
Orthopaedics
119
107
Segment depreciation and amortization
$174
$155
Corporate and Other
$43
$39
Amortization of intangible assets
180
167
Total depreciation and amortization
$397
$361
MedSurg and Neurotechnology
$700
$757
Orthopaedics
846
854
Segment operating income
$1,546
$1,611
Items not allocated to segments:
Corporate and Other
$(275)
$(267)
Inventory stepped up to fair value
(34)
Acquisition and integration-related charges
(19)
(185)
Amortization of intangible assets
(180)
(167)
Structural optimization and other special
charges
(118)
(41)
Goodwill and other impairments
(35)
Medical device regulation
(5)
(12)
Recall-related matters
(10)
(33)
Regulatory and legal matters
(3)
Consolidated operating income
$936
$837
Sales and Other Financial Information by Business Segment
Segment Capital Spending
Three Months
2026
2025
Purchases of property, plant and
equipment:
MedSurg and Neurotechnology
$58
$33
Orthopaedics
41
49
Total segment purchases of property, plant
and equipment
$99
$82
Corporate and Other
67
41
Total purchases of property, plant and
equipment
$166
$123